EMA Recommends Orphan Drug Status for BioInvent’s BI-1808 in Cutaneous T-Cell Lymphoma
As reported by PharmaBiz, the European Medicines Agency’s Committee for Orphan Medicinal Products (COMP) has issued a positive opinion supporting Orphan Drug Designation (ODD) for BioInvent’s BI-1808, an investigational anti-TNFR2…